JP2021512140A5 - - Google Patents

Info

Publication number
JP2021512140A5
JP2021512140A5 JP2020558858A JP2020558858A JP2021512140A5 JP 2021512140 A5 JP2021512140 A5 JP 2021512140A5 JP 2020558858 A JP2020558858 A JP 2020558858A JP 2020558858 A JP2020558858 A JP 2020558858A JP 2021512140 A5 JP2021512140 A5 JP 2021512140A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
methoxyquinoline
ethylpiperazine
methylureido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020558858A
Other languages
English (en)
Japanese (ja)
Other versions
JP7352569B2 (ja
JP2021512140A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/012886 external-priority patent/WO2019139977A1/en
Publication of JP2021512140A publication Critical patent/JP2021512140A/ja
Publication of JP2021512140A5 publication Critical patent/JP2021512140A5/ja
Priority to JP2023149903A priority Critical patent/JP7665700B2/ja
Application granted granted Critical
Publication of JP7352569B2 publication Critical patent/JP7352569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020558858A 2018-01-10 2019-01-09 肝細胞癌の治療のための併用療法 Active JP7352569B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023149903A JP7665700B2 (ja) 2018-01-10 2023-09-15 肝細胞癌の治療のための併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615848P 2018-01-10 2018-01-10
US62/615,848 2018-01-10
PCT/US2019/012886 WO2019139977A1 (en) 2018-01-10 2019-01-09 Combination therapies for the treatment of hepatocellular carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023149903A Division JP7665700B2 (ja) 2018-01-10 2023-09-15 肝細胞癌の治療のための併用療法

Publications (3)

Publication Number Publication Date
JP2021512140A JP2021512140A (ja) 2021-05-13
JP2021512140A5 true JP2021512140A5 (cg-RX-API-DMAC10.html) 2022-01-18
JP7352569B2 JP7352569B2 (ja) 2023-09-28

Family

ID=65411938

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020558858A Active JP7352569B2 (ja) 2018-01-10 2019-01-09 肝細胞癌の治療のための併用療法
JP2023149903A Active JP7665700B2 (ja) 2018-01-10 2023-09-15 肝細胞癌の治療のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023149903A Active JP7665700B2 (ja) 2018-01-10 2023-09-15 肝細胞癌の治療のための併用療法

Country Status (13)

Country Link
US (1) US11833119B2 (cg-RX-API-DMAC10.html)
EP (2) EP3737377B1 (cg-RX-API-DMAC10.html)
JP (2) JP7352569B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250073570A (cg-RX-API-DMAC10.html)
CN (1) CN111787922A (cg-RX-API-DMAC10.html)
AU (1) AU2019206480A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020014112A2 (cg-RX-API-DMAC10.html)
CA (1) CA3088292A1 (cg-RX-API-DMAC10.html)
IL (1) IL275981A (cg-RX-API-DMAC10.html)
MA (1) MA51570A (cg-RX-API-DMAC10.html)
MX (1) MX2020007375A (cg-RX-API-DMAC10.html)
SG (1) SG11202006617RA (cg-RX-API-DMAC10.html)
WO (1) WO2019139977A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533903A (ja) * 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Fgfr4阻害剤の経口製剤によるがんの治療方法
KR20250003965A (ko) 2022-05-30 2025-01-07 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 암 치료용 약학적 조합 및 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
CA2704000C (en) * 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MX2014009303A (es) * 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
CN105338977B (zh) * 2013-06-26 2018-10-16 卫材R&D管理有限公司 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
US10736900B2 (en) * 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US20160089365A1 (en) * 2014-09-25 2016-03-31 Eisai R&D Management Co., Ltd. Immunostimulatory compound
CN107660200B (zh) 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN107304188A (zh) * 2016-04-20 2017-10-31 成都融科博海科技有限公司 一种氘代激酶选择性抑制剂及其应用
JP7372740B2 (ja) * 2016-05-10 2023-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ

Similar Documents

Publication Publication Date Title
JP2019059760A5 (cg-RX-API-DMAC10.html)
ES2393211T3 (es) Uso de 2-aminotetralinas sustituidas para la fabricación de un medicamento para la prevención, alivio y/o tratamiento de diversos tipos de dolor
ES2654787T3 (es) Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento
JP2024540183A5 (cg-RX-API-DMAC10.html)
JP2004525179A5 (cg-RX-API-DMAC10.html)
JP2021152008A5 (cg-RX-API-DMAC10.html)
JP2012162581A (ja) 経口治療用化合物の供給系
WO2002092088A3 (en) Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts
JP2006508953A5 (cg-RX-API-DMAC10.html)
JP2017528507A5 (cg-RX-API-DMAC10.html)
CY1119663T1 (el) Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2
JP2012532874A5 (cg-RX-API-DMAC10.html)
JP2018168191A5 (cg-RX-API-DMAC10.html)
JP2015528471A5 (cg-RX-API-DMAC10.html)
JP2017530983A5 (cg-RX-API-DMAC10.html)
JP2006516570A5 (cg-RX-API-DMAC10.html)
JP2014502979A5 (cg-RX-API-DMAC10.html)
JP2017537899A5 (cg-RX-API-DMAC10.html)
ES2966929T3 (es) Tratamiento de trastornos del movimiento
JP2019515909A5 (cg-RX-API-DMAC10.html)
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
JP2019536812A5 (cg-RX-API-DMAC10.html)
JP2014505107A5 (cg-RX-API-DMAC10.html)
JP2018537507A5 (cg-RX-API-DMAC10.html)
DK1427396T3 (da) Doseringsformer med forlænget frigivelse af aktivt indholdsstof